Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation
Section snippets
Methods
All studies reporting anticoagulation therapy of NVAF in patients >65 years published before May 2020 were identified by the comprehensive computer-based search of PubMed, Cochrane, EmBase, Web of Science, Chinese BioMedical, Global Health, and BIOSIS Previews databases. The following terms were used for search: Atrial fibrillation, nonvalvular, warfarin, anticoagulation. Hand searches for related articles were also performed. All the searches were conducted without language restriction.
Results
With separated search strategy in each database, a total of 1,029 articles that potentially pertinent were retrieved. By reviewing titles and abstracts, irrelevant studies, case reports, and reviews were excluded. Finally, 72 studies were identified for further considerations. Of these, 54 studies were further excluded mainly due to the age of patients included was less than 65 years old (53 studies), or INR ranged 1.6 to 2.5 (one study). Therefore, 18 studies including 2,105 patients (1,058 in
Discussion
NVAF is one of the most common arrhythmia in patients >65 years, which increasing the risk of stroke by 5 times. Stroke not only increases the social disability burden, but also economic burden of public health and medical system.25 It is of great significance to explore an optimal anticoagulation therapy for patients >65 years with NVAF. There have been many studies on anticoagulation therapy of AF, but patients’ age was in a broad range. Studies on populations over 65 years in this field were
Disclosure
All the authors have nothing to disclose.
References (30)
- et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials
Lancet
(2014) - et al.
Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study
Circulation
(2014) - et al.
An epidemiological survey of atrial fibrillation in China
Chin J Intern Med
(2004) - et al.
Effect of pocket irrigation with antimicrobial on prevention of pacemaker pocket infection: a meta-analysis
BMC Cardiovasc Disord
(2017) - et al.
Quantifying heterogeneity in a meta-analysis
Stat Med
(2002) - et al.
Bias in meta-analysis detected by a simple, graphical test
BMJ
(1997) - et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Int J Surg
(2010) - et al.
Effect of warfarin on anticoagulation in elderly patients with atrial fibrillation
Chin J Misdiagn
(2006) - et al.
Efficacy and safety of Warfarin in aged patients with nonvalvular atrial fibrillation
Chin Heart J
(2008) - et al.
Clinical analysis of warfarin low intensity anticoagulation in the elderly patients with permanent non valvular atrial fibrillation
Chin J Pract Med
(2008)
Observation of anticoagulant therapy with different intensity in elderly patients with chronic non-valvular atrial fibrillation
J Pract Med
Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation
Cardiovas Bio Cell Signa
Safety and efficacy of low intensity anticoagulant therapy in patients with atrial fibrillation over 80 years old
Chin J Geriatr
Comparison of antithrombotic efficacy and safety of different doses of warfarin and aspirin in elderly patients with persistent atrial fibrillation
South Chin J Cardiov Disea
Cited by (4)
Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants
2022, IJC Heart and VasculatureCitation Excerpt :Compared with NAT or AP, NVAF patients treated with VKA or NOAC had a better prognosis, with lower all-cause death (χ2 = 58.05, p < 0.001), lower stroke incidence (χ2 = 31.50, p < 0.001), lower CRNM GIB incidence (χ2 = 25.71, p < 0.001), and no increase in MB events (χ2 = 2.91, p = 0.406). For very elderly patients with NVAF, lower dosages of NOACs were used or lower INR target of VKA was achieved (e.g., dabigatran 110 mg twice daily, rivaroxaban 15 mg once daily, edoxaban 30 mg once daily, apixaban 2.5 mg twice daily, warfarin INR target 1.6–2.6) [10–14]. Decisions to prescribe reduced dose NOACs or low INR target VKA are made based on the specific considerations on age, weight, renal function and use of specific concomitant medications.
Standard-Intensity Versus Low-Intensity Anticoagulation with Warfarin in Asian Patients with Atrial Fibrillation: A Multi-Center, Randomized Controlled Trial
2023, Clinical and Applied Thrombosis/Hemostasis
Funding Sources: This work is supported by the Natural Science Foundation of Guangdong Province of China (Grant No.2016A030313794); Guangdong Provincial Bureau of traditional Chinese Medicine (Grant No.20191315); Research Fund for Compound Danshen Dripping Pills (Grant No.K0601192). The funding organizations did not have any role in the study design, collection, analysis, or interpretation of data, in writing of the manuscript, or in the decision to submit the article for publication. The researchers were independent from the funding organizations.